AstraZeneca Snuffs Out ‘Promise of the Patent’ Rule. Now What?
We asked Richard Gold of McGill University's Centre for Intellectual Property Policy to explain what last week's decision from the Supreme Court of Canada means for innovation, competition and patent quality.
This premium content is reserved for CC Corporate Counsel subscribers.
Continue reading by getting started with a subscription.
Already a subscriber? Log in now